bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary methods and Supplementary Figures S1-S8 from BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway
Authors: Chen Xiaohui , Cao Xihua , Tu Xuhuang , Alitongbieke Gulimiran , Xia Zebin , Li Xiaotong , Chen Ziwen , Yin Meimei , Xu Dan , Guo Shangjie , Li Zongxi , Chen Liqun , Zhang Xindao , Xu Dingyu , Gao Meichun , Liu Jie , Zeng Zhiping , Zhou Hu , Su Ying , Zhang Xiao-kun
Published: April 2023

The Supplementary Methods show the Synthesis of DIM-C-pPhCF3+MeSO3- (BI1071); Figure S1 shows BI1071 induces apoptosis in different cancer cell lines; Fig. S2 shows BI1071 induces apoptosis in different breast cancer cell lines; Fig. S3 shows BI1071 induces apoptosis in cancer cell lines but not in non-transformed cell lines; Fig. S4 shows BI1071 did't induce the body weight loss; Fi.g S5 shows overexpression of Nur77-LBD enhances the killing effect of BI1071; Fig. S6 shows BI1071 has no effect on other nuclear receptors; Fig. S7 shows the imparied effect of BI1071 could be rescued by re-expression of Bcl-2; Fig. S8 shows BI1071 binding to Nur77 promotes Nur77 interaction with Bcl-2 and mitochondrial localization
Supplementary Tables S1-S3 from BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Authors: Stagni Camilla , Zamuner Carolina , Elefanti Lisa , Zanin Tiziana , Bianco Paola Del , Sommariva Antonio , Fabozzi Alessio , Pigozzo Jacopo , Mocellin Simone , Montesco Maria Cristina , Chiarion-Sileni Vanna , De Nicolo Arcangela , Menin Chiara
Published: April 2023

Table S1. Nucleotidic sequences of primers and probes used in the qPCR analyses. Table S2. Detailed description of BRAF copy number (CN) and mutant-allele specific quantification results. Table S3. Analysis of the association between BRAF copy number and mutant allele frequency with best response by Fisher''s exact test.
Supplementary Figure 3 from Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
Authors: Fischl Anthony S. , Wang Xiaoen , Falcon Beverly L. , Almonte-Baldonado Rowena , Bodenmiller Diane , Evans Glenn , Stewart Julie , Wilson Takako , Hipskind Philip , Manro Jason , Uhlik Mark T. , Chintharlapalli Sudhakar , Gerald Damien , Alsop David C. , Benjamin Laura E. , Bhatt Rupal S.
Published: April 2023

Figure S3: S1P1 is largely restricted to tumor vessels. Six different tumor models were assessed for S1P1 expression by immunofluorescence. In five of the models S1P1 expression was restricted to tumor vessels. The SK-Hep 1 tumor model was the only model in which some S1P1 expression was also seen on tumor cells in addition to on tumor vessels.
Supplemental Table S1 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Analysis of correlation between the presence of AKT1-E17K mutation and clinical aspects.
Supplementary Figure 2 from Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
Authors: Fischl Anthony S. , Wang Xiaoen , Falcon Beverly L. , Almonte-Baldonado Rowena , Bodenmiller Diane , Evans Glenn , Stewart Julie , Wilson Takako , Hipskind Philip , Manro Jason , Uhlik Mark T. , Chintharlapalli Sudhakar , Gerald Damien , Alsop David C. , Benjamin Laura E. , Bhatt Rupal S.
Published: April 2023

Figure S2: Co-targeting S1P1 and VEGFR2 pathways induced reduction in permeability of retinal vessels. Ter 119 staining (panels A) visualize red blood cells and show that the combination of DC101 and the S1P1 antagonist in the retina led to reduction of the areas of hemorrhage within the vascular plexus and restricted only to the angiogenic front indicating that the remaining vessels in the remodeled area are less permeable.
Supplementary Figure 1 from Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
Authors: Fischl Anthony S. , Wang Xiaoen , Falcon Beverly L. , Almonte-Baldonado Rowena , Bodenmiller Diane , Evans Glenn , Stewart Julie , Wilson Takako , Hipskind Philip , Manro Jason , Uhlik Mark T. , Chintharlapalli Sudhakar , Gerald Damien , Alsop David C. , Benjamin Laura E. , Bhatt Rupal S.
Published: April 2023

Figure S1: Impedance barrier function assay: The effect of S1P and Ex82 was analyzed using a transendothelial electrical impedance assay. S1P treatment (10 nM) of an endothelial monolayer strongly increases electrical impedance (B) vs control (A) whereas Ex82 has the opposite effect and significantly decreases electrical impedance (D). These results are consistent with the known barrier function of S1P1. In addition, pretreatment with Ex82 blocked the S1P dependent increase in electrical impedance (C).
Supplemental Figure 4 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Fig. 4. Senescent cells in tumors. Number of senescent cells (β-Gal+ cells) in different xenograft models. Error bars indicate mean {plus minus} SEM.
Supplemental Figure 3 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Fig. 3. AKT1-WT versus AKT1-E17K: Functional assays in vitro (Part 2). Bar plots for functional assays performed three days after induction of AKT1-WT or AKT1-E17K protein for colony formation (on plastic), migration, invasion (in matrigel), colony formation (soft-agar), or growth as multicellular tumor spheroids in suspension. Error bars indicate mean {plus minus} SEM.
Table S5 from Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy
Authors: Chen Hui , Luthra Rajyalakshmi , Routbort Mark J. , Patel Keyur P. , Cabanillas Maria E. , Broaddus Russell R. , Williams Michelle D.
Published: April 2023

Clinical characteristics of 39 poorly differentiated thyroid carcinoma patients
Table S4 from Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy
Authors: Chen Hui , Luthra Rajyalakshmi , Routbort Mark J. , Patel Keyur P. , Cabanillas Maria E. , Broaddus Russell R. , Williams Michelle D.
Published: April 2023

Comparison of mutational frequency of advanced MDACC thyroid cohort versus well-differentiated papillary thyroid cancers from the TCGA
Supplemental Figure 1 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Fig. 1. AKT1-WT, AKT1-E17K, and downstream signaling. Immunoblots using indicated anibodies of lysates from cancer cell three days after induction of AKT1-WT or AKT1-E17K protein.
Methods from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Methods
Table S1 from Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy
Authors: Chen Hui , Luthra Rajyalakshmi , Routbort Mark J. , Patel Keyur P. , Cabanillas Maria E. , Broaddus Russell R. , Williams Michelle D.
Published: April 2023

List of genes in Ion AmpliSeq Cancer Panel
Supplemental Figures 1-7 and Tables 1-2 from Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
Authors: Narayan Ravi S. , Gasol Ana , Slangen Paul L.G. , Cornelissen Fleur M.G. , Lagerweij Tonny , Veldman Hou Y.Y.E. , Dik Rogier , van den Berg Jaap , Slotman Ben J. , Würdinger Tom , Haas-Kogan Daphne A. , Stalpers Lukas J.A. , Baumert Brigitta G. , Westerman Bart A. , Theys Jan , Sminia Peter
Published: April 2023

Supplemental Figure 1. Chemical structures of non-FDA approved compounds used in the Study; Supplemental Figure 2. Effect of drugs on growth and target phosphorylation; Supplemental Figure 3. mTOR inhibition does not show dose dependent Radiosensitization; Supplemental Figure 4. MEK162 + RT abrogate spheroid regrowth; Supplemental Figure 5. MEK162 radiosensitizes GBM8 primary spheroid culture and increases γH2AX levels; Supplemental Figure 6. MEK162 abrogates BrdU washout and increases sub-G1 accumulation of BrdU+ cells; Supplemental Figure 7. MEK162 + RT in vivo; Supplemental Table 1: Antibodies used; Supplemental Table 2: Gene signature MEK+RT response
Table S1 from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Assignment of MSE fragmentation data for protease-digested peptide with TAS6417
Supplementary Video 5 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 5 shows a confocal time-lapse series, showing MDCK cells treated with 40 ug of K16ApoE, immediately after labeling with Calcein-AM (green), which indicates live cells, and Ethidium homodimer-1 (red), indicating dead cells.
Supplementary Methods from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Methods for in vitro kinase assay, genome sequence, and immunoblotting analysis
Figure S3 from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Body weight change resulting from once-daily oral administration of TAS6417
Figure S2 from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Establishment of a cell line tool with an EGFR exon 20 insertion mutation
Figure S1 from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Synthesis procedures and characterization data for the synthesis of TAS6417
Tables_S3_S5 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S3: Intronic retention events in PRPF8-KD and PRPF38A-KD cells; Table S5: Differentially expressed genes in PRPF38A-KD cells
Tables S8-S9 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S8: Enriched Reactome modules in shared PRPF8-KD and PRPF38A-KD up-regulated transcripts; Table S9: Enriched Reactome modules in shared PRPF8-KD and PRPF38A-KD down-regulated transcripts
Supplementary Materials from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Materials shows supplementary methods, Supplementary Figures S1-S9 with legends and Supplementary Table 1. Supplementary Table 1: Mean Ve, Kep and AUC after DCE-MRI; Supplementary Figure S1: In vivo study design; Supplementary Figure S2: Blood smear from mice subjected to 1,000 µg K16ApoE; Supplementary Figure S3: In vitro cell viability: Supplementary Figure S4: Mechanistic studies of the in vitro effects of K16ApoE; Supplementary Figure S5: In vitro BBB model; Supplementary Figure S6: Biodistribution of 125I-K16ApoE; Supplementary Figure S7: Histopathological evaluation of tissue samples after long- and short-term treatment of NOD/SCID mice with the peptide; Supplementary Figure S8: In vivo treatment control experiment; Supplementary Figure S9: Mass spectrometry of treated and untreated brain tissue
Tables S12-S13 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S12: Enriched Reactome modules in the top 1,000 up-regulated transcripts in Table S11; Table S13: Enriched Reactome modules in the top 1,000 down-regulated transcripts in Table S11
Table S11 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Table S11: Differentially expressed transcripts in E7107- vs DMSO-treated MB468 cells
Supplementary Data from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Supplementary Materials and Methods, Figure Legends and Table Legends
Figures S1-S7 from Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival
Authors: Chan Stefanie , Sridhar Praveen , Kirchner Rory , Lock Ying Jie , Herbert Zach , Buonamici Silvia , Smith Peter , Lieberman Judy , Petrocca Fabio
Published: April 2023

Figure S1: Core RNA splicing genes are frequently up-regulated in basal-like TNBC; Figure S2: PRPF8 and PRPF38A knockdown have similar effect based on gene expression; Figure S3: PRPF8 knockdown promotes G2/M arrest and histone-H3 phosphorylation in MB468 cells ;Figure S4: Ribosomal, immune response, cell cycle, mitosis and proteasome transcripts are commonly sensitive to PRPF8 knockdown across different cell lines. ;Figure S5: PRPF8 knockdown disrupts MCL1 splicing across different cell lines. ;Figure S6: MB468 and HCC1187 cells are sensitive to siRNA-mediated SF3B1 knockdown; Figure S7: E7107 suppresses HCC1187 xenograft growth at a well-tolerated dose
Supplementary Table 2 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

Oligonucleotide sequence of qRT-PCR primers
Supplemental Table 1 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

Demographic and clinical characteristics of patients treated with belinostat and panobinostat with archived tumor tissue available for study.
Supplementary Table 1 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

The catalog number of antibodies, blocking reagent and dilutions.
Supplemental Figure 3 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

Heat map of top 50 genes affected in HT1197 cells when treated with panobinostat at 48 hours log2 gene expression change(HT1197 A-B and C represent control replicates, HT1197 Pano A, B, C represent treated replicates). For the cell lines with replicates, statistically significant genes were identified with a FDR of <1% and absolute fold change > 2 fold. Plot was generated with R using median-centered regularized log2 values.
Supplementary Figure 3 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

PRL-3 up-regulates the expression of CCL26 in HT29 cell
Supplemental Tables 1-4 from Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer
Authors: Humphries-Bickley Tessa , Castillo-Pichardo Linette , Hernandez-O’Farrill Eliud , Borrero-Garcia Luis D. , Forestier-Roman Ingrid , Gerena Yamil , Blanco Manuel , Rivera-Robles Michael J. , Rodriguez-Medina José R. , Cubano Luis A. , Vlaar Cornelis P. , Dharmawardhane Suranganie
Published: April 2023

Supplemental Table 1: Effect of MBQ-167 on Rho GTPase activity (Active Rho GTPase/Total Rho GTPase) following 24 h in MDA-MB-231 cells, relative to vehicle (=1); Supplemental Table 2: Effect of MBQ-167 on Rac activity (Active Rac/Total Rac) following 24 h in MCF-7 cells; Supplemental Table 3: Optimal %Treated (T)/Control (C) for mammary fat pad tumor growth for EHop-167 treated nude mice; Supplemental Table 4: Tumor growth delay for EHop-167-treated mice
Supplemental Figure S7 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

FRA expression on regrown MORAb-202-treated LXFA-737 non-small cell lung carcinoma PDX tumors
Supplemental Figures 1-10 from Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer
Authors: Humphries-Bickley Tessa , Castillo-Pichardo Linette , Hernandez-O’Farrill Eliud , Borrero-Garcia Luis D. , Forestier-Roman Ingrid , Gerena Yamil , Blanco Manuel , Rivera-Robles Michael J. , Rodriguez-Medina José R. , Cubano Luis A. , Vlaar Cornelis P. , Dharmawardhane Suranganie
Published: April 2023

Supplemental Figure 1: Molecular docking of EHop-016 and MBQ-167 into the effector domain of Rac1; Supplemental Figure 2: Cancer cell phenotype following EHop-167 treatment; Supplemental Figure 3: Effect of MBQ-167 on Rac activity of MDA-MB-231 cells following 6 h of treatment; Supplemental Figure 4: Effect of MBQ-167 on Rho GTPase activity in GFP-HER2-BM cells; Supplemental Figure 5: MBQ-167 does not affect PAK activity in MCF-7 cells; Supplemental Figure 6: Effect of MBQ-167 on STAT3 activation and cell migration in GFP-HER2-BM metastatic cancer cells; Supplemental Figure 7: MAPK and Akt signaling in MDA-MB-231 cells; Supplemental Figure 8: Effect of 24 h treatment of MBQ-167 on breast cancer cell survival; Supplemental Figure 9: Annexin V staining in response to MBQ-167; Supplemental Figure 10: Effect of MBQ-167 on bud polarity in Saccharomyces cerevisiae.
Supplemental Figure S5 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

Specificity of MORAb-202 cytotoxicity
Video 4 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Authors: Karlin Jeremy , Allen Jasmine , Ahmad Syed F. , Hughes Gareth , Sheridan Victoria , Odedra Rajesh , Farrington Paul , Cadogan Elaine B. , Riches Lucy C. , Garcia-Trinidad Antonio , Thomason Andrew G. , Patel Bhavika , Vincent Jennifer , Lau Alan , Pike Kurt G. , Hunt Thomas A. , Sule Amrita , Valerie Nicholas C.K. , Biddlestone-Thorpe Laura , Kahn Jenna , Beckta Jason M. , Mukhopadhyay Nitai , Barlaam Bernard , Degorce Sebastien L. , Kettle Jason , Colclough Nicola , Wilson Joanne , Smith Aaron , Barrett Ian P. , Zheng Li , Zhang Tianwei , Wang Yingchun , Chen Kan , Pass Martin , Durant Stephen T. , Valerie Kristoffer
Published: April 2023

U87/Centrin2-EGFP/H2B-mCherry/shp53(shp53) cells were seeded on dishes with cover slip bottoms, treated with AZ32 (3 uM), and irradiated (5 Gy). Time-lapse videos were recorded intermittently (every 7 min) over 16 hrs. Treatment results in 46% aberrant mitoses (see Fig. 3F).
Supplemental Figure S4 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

Biophysical analyses of MORAb-202 large-scale conjugation.
Supplemental Figure S3 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

Analyses of faletuzumab and amatuximab ADCs
Supplementary Information from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Authors: Karlin Jeremy , Allen Jasmine , Ahmad Syed F. , Hughes Gareth , Sheridan Victoria , Odedra Rajesh , Farrington Paul , Cadogan Elaine B. , Riches Lucy C. , Garcia-Trinidad Antonio , Thomason Andrew G. , Patel Bhavika , Vincent Jennifer , Lau Alan , Pike Kurt G. , Hunt Thomas A. , Sule Amrita , Valerie Nicholas C.K. , Biddlestone-Thorpe Laura , Kahn Jenna , Beckta Jason M. , Mukhopadhyay Nitai , Barlaam Bernard , Degorce Sebastien L. , Kettle Jason , Colclough Nicola , Wilson Joanne , Smith Aaron , Barrett Ian P. , Zheng Li , Zhang Tianwei , Wang Yingchun , Chen Kan , Pass Martin , Durant Stephen T. , Valerie Kristoffer
Published: April 2023

Supplementary Information
Table S2 from Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin
Authors: Zhang Yong , Dong Yinhui , Melkus Michael W. , Yin Shutao , Tang Su-Ni , Jiang Peixin , Pramanik Kartick , Wu Wei , Kim Sangyub , Ye Min , Hu Hongbo , Lu Junxuan , Jiang Cheng
Published: April 2023

Table S2 shows down-regulated genes by 10 nM bufalin over vehicle control by over 40% or more in LNCaP cells exposed for 24 h. Expressed as fold over vehicle control set as unity.
Supplementary Figure S4 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S4. Amino acid sequences near phosphorylated residues of mammalian RIs. Phosphoryl groups on these residues interact favorably with a ptRNase (Fig. 5E).
Supplementary Materials and Methods from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
Authors: Theunissen Jan-Willem , Cai Allen G. , Bhatti Maryam M. , Cooper Anthony B. , Avery Andrew D. , Dorfman Ryan , Guelman Sebastian , Levashova Zoia , Migone Thi-Sau
Published: April 2023

Supplementary Materials and Methods
Supplementary Materials and Methods from Targeting PRPK Function Blocks Colon Cancer Metastasis
Authors: Zykova Tatyana , Zhu Feng , Wang Lei , Li Haitao , Lim Do Young , Yao Ke , Roh Eunmiri , Yoon Sang-Pil , Kim Hong-Gyum , Bae Ki Beom , Wen Weihong , Shin Seung Ho , Nadas Janos , Li Yan , Ma Weiya , Bode Ann M. , Dong Zigang
Published: April 2023

Supplementary Materials and Methods
Supplementary Figures and Legends from Targeting PRPK Function Blocks Colon Cancer Metastasis
Authors: Zykova Tatyana , Zhu Feng , Wang Lei , Li Haitao , Lim Do Young , Yao Ke , Roh Eunmiri , Yoon Sang-Pil , Kim Hong-Gyum , Bae Ki Beom , Wen Weihong , Shin Seung Ho , Nadas Janos , Li Yan , Ma Weiya , Bode Ann M. , Dong Zigang
Published: April 2023

This file contains 7 Supplementary Figures and associated legends: Supplementary Figure 1. Characterization of the antibody to detect phosphorylated Ser250of PRPK (related to Figure 1B, upper). Supplementary Figure 2. PRPK induces metastasis of colon cancer cells to the liver. Supplementary Figure 3. PRPK induces lung metastasis of human HCT116 or mouse CT26 colon cancer cells. Supplementary Figure 4. EGF induces phosphorylation of PRPK and surviving ex vivo and the combination of 5-FU and FA show synergistic effects against colon cancer growth. Supplementary Figure 5. Pre-treatment with FA combined with 5-FU suppresses colon lung metastasis in mice. Supplementary Figure 6. FA combined with 5-FU suppresses colon lung metastasis in mice Supplementary Figure 7. PRPK regulated colon cancer metastasis independently of p53 status.
Supplementary Table II from HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation
Authors: Efimova Elena V. , Ricco Natalia , Labay Edwardine , Mauceri Helena J. , Flor Amy C. , Ramamurthy Aishwarya , Sutton Harold G. , Weichselbaum Ralph R. , Kron Stephen J.
Published: April 2023

Supplementary Table 2. This is a list of all the antibodies used in the study.
Supplementary Table S2 from JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers
Authors: Pitroda Sean P. , Stack Melinda E. , Liu Gene-Fu , Song Sui-Sui , Chen Lucy , Liang Hua , Parekh Akash D. , Huang Xiaona , Roach Paul , Posner Mitchell C. , Weichselbaum Ralph R. , Khodarev Nikolai N.
Published: April 2023

Supplementary Table 2. Gene expression patterns correlating with SAR sensitivity.
Supplementary Figures S1-S8 and Legends from HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation
Authors: Efimova Elena V. , Ricco Natalia , Labay Edwardine , Mauceri Helena J. , Flor Amy C. , Ramamurthy Aishwarya , Sutton Harold G. , Weichselbaum Ralph R. , Kron Stephen J.
Published: April 2023

Supplementary Fig. S1. Identification of pitavastatin in IRIF persistence screen of NIH Clinical Collection in MCF7GFP-IBD and PANC02GFP-IBD cell lines; Supplementary Fig. S2. Mevalonic acid abrogates radiosensitization effects of pitavastatin in irradiated MCF7 GFP-IBD cells. Supplementary Fig. S3. Reduction in targeted protein expression by shRNA; Supplementary Fig. S4. Targeting mevalonate pathway affects protein prenylation; Supplementary Fig. S5. Farnesyl pyrophosphate abrogates radiosensitization effects of statins in irradiated MCF7 GFP-IBD cells; Supplementary Fig. S6. Silencing GGPS impacts DNA damage response; Supplementary Fig. S7. Clonogenic survival of B16.SIY cells treated with 5 μmol/L or 10 μmol/L veliparib 1 hour prior to the indicated irradiation dose; Supplementary Fig. S8. Flow cytometry co-staining assay for apoptosis and necrosis in tumor cells treated with pitavastatin and/or radiation.
Supplementary Materials and Methods from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Supplementary Materials and Methods
Supplemental Figures w/ Legends from Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition
Authors: Young Alexandria N. , Herrera Denisse , Huntsman Andrew C. , Korkmaz Melissa A. , Lantvit Daniel D. , Mazumder Sarmistha , Kolli Shamalatha , Coss Christopher C. , King Salane , Wang Hongyan , Swanson Steven M. , Kinghorn A. Douglas , Zhang Xiaoli , Phelps Mitch A. , Aldrich Leslie N. , Fuchs James R. , Burdette Joanna E.
Published: April 2023

SF1: Synthesis & characterization of PHYs, SF2: Purity of PHYs, SF3: PHY34 cytotoxicity in various cancer types, SF4: Additional in vivo data, SF5: PHY25 & 30 cytotoxicity time course.
Supplementary Figures S1-S6 from Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations
Authors: Yamada Tadaaki , Amann Joseph M. , Tanimoto Azusa , Taniguchi Hirokazu , Shukuya Takehito , Timmers Cynthia , Yano Seiji , Shilo Konstantin , Carbone David P.
Published: April 2023

Sup. Figure 1: The effect of MEK and HDAC inhibition on total FOXO1, FOXO3a, cell apoptosis, and cell cycle proteins in a fibroblast cell line; Sup. Figure 2: The effect of single agent trametinib and belinostat and the combination on metabolic activity of human lung embryonic fibroblast cells; Sup. Figure 3: FOXO transcriptional activity is increased in RAS mutated lung cancer cells by treatment with belinostat or the combination of belinostat and trametinib; Sup. Figure 4: The knockdown of FOXO1, FOXO3a, and BIM in RAS mutated lung cancer cells; Sup. Figure 5: The knockdown of FOXO1 or FOXO3a suppressed the expression of BIM and cleaved PARP when treated with the combination of trametinib and belinostat in RAS mutated lung cancer cells; Sup. Figure 6: The combination of trametinib and belinostat shows increased efficacy in a xenograft model of KRAS mutated lung cancer and is well tolerated.
Figure S5 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

MLKL-dependent cell death in TOV112D ovarian cancer cells.
Supplementary Figure legends from Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations
Authors: Yamada Tadaaki , Amann Joseph M. , Tanimoto Azusa , Taniguchi Hirokazu , Shukuya Takehito , Timmers Cynthia , Yano Seiji , Shilo Konstantin , Carbone David P.
Published: April 2023

Sup Figure legend 1-6
Figure S4 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Ceramide nanoliposomes treatment promoted the oligomerizations of endogenous MLKL.
Supplemental Table S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Authors: Dong Jun , Wu Zeyu , Wang Dan , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Proteins interacting with AR identified by High Accuracy Mass Spectrometer.
Figure S1 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of ceramide nanoliposomes on cell viability in multiple ovarian cancer cell lines.
Supplemental Figure S2 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Authors: Dong Jun , Wu Zeyu , Wang Dan , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplemental Figure S2 shows the co-immunoprecipitation of SBD and AR truncated mutations.
Supplemental Figure Legend from A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
Authors: Steuer Conor E. , Griffith Christopher C. , Nannapaneni Sreenivas , Patel Mihir R. , Liu Yuan , Magliocca Kelly R. , El-Deiry Mark W. , Cohen Cynthia , Owonikoko Taofeek K. , Shin Dong M. , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PD-L1 and PD-1 Immunohistochemistry
Table S1 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

74 candidate target genes of MIRTX in DLD1
Figure S1 from A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
Authors: Steuer Conor E. , Griffith Christopher C. , Nannapaneni Sreenivas , Patel Mihir R. , Liu Yuan , Magliocca Kelly R. , El-Deiry Mark W. , Cohen Cynthia , Owonikoko Taofeek K. , Shin Dong M. , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PD-L1 and PD-1 Immunohistochemistry
Fig. S6 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S6. Initial screening for candidate miRNAs that could target KRAS mutant CRC. Inhibitory effects of 6 miRNAs on proliferation of KRAS mutant and KRAS wild-type CRC cell lines. Mimic-miR-29b-1-5p showed a significant inhibition of cell proliferation in all CRC cell lines at 72h. All data represent mean {plus minus} SD. *p < 0.01. Six miRNAs were additionally identified in our previous study (21) by introducing mutant KRASG12V plasmid into HEK293 and MRC5 cells, followed by miRNA microarray analysis.
Fig. S3 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S3. Hypothetical and conclusive schematic illustration of each signaling pathway. (A) A hypothetical schematic illustration of each signaling pathway. Could a novel anti-tumor RNA sequence named "MIRTX" directly target PIK3R1 and CXCR2, leading to suppression of NF-κB and PI3K/AKT/mTOR signaling pathways in KRAS mutant CRC? (B) A conclusive scheme of each signaling pathway. A novel anti-tumor small RNA sequence named "MIRTX" directly targets PIK3R1 and CXCR2, leading to suppression of NF-κB signaling pathways in KRAS mutant CRC, triggering apoptosis; however, PI3K/AKT/mTOR pathway was maintained, possibly by a feedback regulatory mechanism.
Table S1 from KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Authors: Nakatani Kaori , Yamaoka Toshimitsu , Ohba Motoi , Fujita Ken-Ichi , Arata Satoru , Kusumoto Sojiro , Taki-Takemoto Iori , Kamei Daisuke , Iwai Shinichi , Tsurutani Junji , Ohmori Tohru
Published: April 2023

Proportions of EGFR exon 19 del and T790M alleles in OsiR1-F2M and OsiR2-F2M cells.
Figure S4 from KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Authors: Nakatani Kaori , Yamaoka Toshimitsu , Ohba Motoi , Fujita Ken-Ichi , Arata Satoru , Kusumoto Sojiro , Taki-Takemoto Iori , Kamei Daisuke , Iwai Shinichi , Tsurutani Junji , Ohmori Tohru
Published: April 2023

Association phospho-EGFR (Y1068) and the GRB2/SOS1 complex sustained KRAS activity and led to osimertinib resistance.
Table S1 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
Authors: Tanaka Hiroshi , Sase Hitoshi , Tsukaguchi Toshiyuki , Hasegawa Masami , Tanimura Hiromi , Yoshida Miyuki , Sakata Kiyoaki , Fujii Toshihiko , Tachibana Yukako , Takanashi Kenji , Higashida Atsuko , Hasegawa Kiyoshi , Ono Yoshiyuki , Oikawa Nobuhiro , Mio Toshiyuki
Published: April 2023

Cell line information and sensitivity to CH7057288 in high-throughput assay systems.
Figures S1-5 & Tables S2-5 from Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer
Authors: Tanaka Hiroshi , Sase Hitoshi , Tsukaguchi Toshiyuki , Hasegawa Masami , Tanimura Hiromi , Yoshida Miyuki , Sakata Kiyoaki , Fujii Toshihiko , Tachibana Yukako , Takanashi Kenji , Higashida Atsuko , Hasegawa Kiyoshi , Ono Yoshiyuki , Oikawa Nobuhiro , Mio Toshiyuki
Published: April 2023

Figure S1. Chemical structure, Figure S2. Kinase selectivity, Figure S3. PK, Figure S4. Inhibition of proliferation and induction of apoptosis in vivo, Figure S5. TP53 sequencing, Table S2. Crystallographic data collection, Table S3. Genes changed by 1 uM CH7057288 treatment, Table S4. Upstream regulators, Table S5. The Caco-2 permeability assay
Figure S2 from KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Authors: Nakatani Kaori , Yamaoka Toshimitsu , Ohba Motoi , Fujita Ken-Ichi , Arata Satoru , Kusumoto Sojiro , Taki-Takemoto Iori , Kamei Daisuke , Iwai Shinichi , Tsurutani Junji , Ohmori Tohru
Published: April 2023

RocR1 and RocR2 showed KRAS and EGFR gene amplifications, respectively, with loss of exon 19 deletion and T790M in EGFR following acquisition of rociletinib resistance.
Figure S1 from KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Authors: Nakatani Kaori , Yamaoka Toshimitsu , Ohba Motoi , Fujita Ken-Ichi , Arata Satoru , Kusumoto Sojiro , Taki-Takemoto Iori , Kamei Daisuke , Iwai Shinichi , Tsurutani Junji , Ohmori Tohru
Published: April 2023

RocR1 and RocR2 cells showed loss of exon 19 deletion and T790M in EGFR following acquisition of rociletinib resistance.
Figure S1 from Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity
Authors: Rath Barbara H. , Waung Isabella , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

A)Effect of radiation on H3K27me3 levels in U251 cells. B)Effects of GSKJ4 on cell cycle distribution of U251 or MDA-MB-231 cells.
Table S3 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

ABC transporter family member genes up-regulated in Raji/253R cells
Table S2 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

Rank order of genes up-regulated in Raji/253R cells.
Table S1 from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

Rate of efflux of APTO-253 and Fe(253)3 from Raji and Raji/253R cells over first 2 hours (log fmole/10^7 cells/h)
Supplementary Figure Legends from CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
Authors: Drake Penelope M. , Carlson Adam , McFarland Jesse M. , Bañas Stefanie , Barfield Robyn M. , Zmolek Wesley , Kim Yun Cheol , Huang Betty C.B. , Kudirka Romas , Rabuka David
Published: April 2023

Supplementary Figure Legends
Supplementary Figures 1-3 and Table 1. from CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
Authors: Suda Kenichi , Murakami Isao , Yu Hui , Kim Jihye , Tan Aik-Choon , Mizuuchi Hiroshi , Rozeboom Leslie , Ellison Kim , Rivard Christopher J. , Mitsudomi Tetsuya , Hirsch Fred R.
Published: April 2023

Supplementary Figure 1. EMT status in HCC827 lung cancer cells and their EGFR-TKI resistant daughter cell lines. Supplementary Figure 2. CD44 is overexpressed in lesions with mesenchymal phenotype after acquisition of resistance to EGFR-TKIs (Patient 1). The results of IHC staining for isogenic lesions obtained from a lung adenocarcinoma patient who acquired resistance to gefitinib monotherapy are shown. Supplementary Figure 3. CD44 is overexpressed in lesions with mesenchymal phenotype after acquisition of resistance to EGFR-TKIs (Patient 2). The results of IHC staining for isogenic lesions obtained from a lung adenocarcinoma patient who acquired resistance to afatinib monotherapy are shown. Supplementary Table 1. Summary of genetic features of TKI resistant cell lines used in this study.
Supplementary Table S1 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Validation of cell lines
Figure S7 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Effects of GW9662 and T0070907 on two LTED breast cancer cells. A, DNA Growth assay of GW9662 in MCF-7:5C cells. Cells were treated with E2 (1 nM), GW9662 (10, 20 µM), or a combination of them for 7 days. Cells were harvested for DNA proliferation assay. **P<0.001. B, DNA Growth assay of GW9662 in MCF-7:2A cells. Cells were treated with E2 (1 nM), GW9662 (10, 20 µM), or a combination of them for 7 days. Cells were harvested for DNA proliferation assay. *P<0.05, **P<0.001. C, MCF-7:5C cells were treated with E2 (1 nM), T0070907 (5 µM), or a combination of them for 4 days. Cells were then harvested in TRIzol reagent. TNFα expression was quantitated by RT-PCR. **P<0.001. D, T0070907 inhibited phosphorylation of Akt in MCF-7:5C cells. Cells were treated with T0070907 (5 µM) for indicated times. Phosphor-Akt and total Akt were detected using Western blotting. E, MCF-7:5C cells were treated with E2 (1 nM), T0070907 (5 µM), or a combination of them for 72 hours. Cells were then harvested in TRIzol reagent. pS2 expression was quantitated by RT-PCR. **P<0.001. F, MCF-7:2A Cells were treated with E2 (1 nM), T0070907 (2.5 µM), or a combination of them for 72 hours. Cells were then harvested in TRIzol reagent. pS2 expression was quantitated by RT-PCR. *P<0.05, **P<0.001.
Figure S6 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Effective knockdown of PPARγ at RNA levels in LTED breast cancer cell lines. A, MCF-7:5C cells were transfected with scrambled siRNA or specific PPARγ siRNA for 72 hours. Next, cells were treated with a vehicle control (0.1% EtOH) or E2 (1nM) for 48 hours. Cells were then harvested in TRIzol reagent. PPARγ expression levels were quantitated using RT-PCR. **P<0.001 compared with control. B, MCF-7:2A cells were double transfected with scrambled siRNA or specific PPARγ siRNA for 5 days. Next, cells were treated with a vehicle control (0.1% EtOH) or E2 (1nM) for 72 hours. Cells were then harvested in TRIzol reagent. PPARγ expression levels were quantitated using RT-PCR. **P<0.001 compared with control. C, T47D:C42 cells were transfected with scrambled siRNA or specific PPARγ siRNA for 72 hours. Then, cell lysates were harvested to measure PPARγ, cleaved PARP, and ERα by Western blot. D, MCF-7:5C cells were transfected with scrambled siRNA or specific PPARγ siRNA for 72 hours. Next, cells were treated with a vehicle control (0.1% EtOH) or E2 (1nM) for 72 hours. Cells were then harvested for annexin V/PI staining. **P<0.001 compared with control. E, MCF-7:2A cells were double transfected with scrambled siRNA or specific PPARγ siRNA for 5 days. Next, cells were treated with a vehicle control (0.1% EtOH) or E2 (1nM) for 6 days. Cells were then harvested for annexin V/PI staining. *P<0.05, **P<0.001 compared with control.